About: Letter to the Editor in relation to Bistrian BR. Parenteral fish oil emulsions in critically ill COVID‐19 emulsions [published online ahead of print, 2020 May 8]. JPEN J Parenter Enteral Nutr. 2020;10.1002/jpen.1871

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Letter to the Editor in relation to Bistrian BR. Parenteral fish oil emulsions in critically ill COVID‐19 emulsions [published online ahead of print, 2020 May 8]. JPEN J Parenter Enteral Nutr. 2020;10.1002/jpen.1871 Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Letter to the Editor in relation to Bistrian BR. Parenteral fish oil emulsions in critically ill COVID‐19 emulsions [published online ahead of print, 2020 May 8]. JPEN J Parenter Enteral Nutr. 2020;10.1002/jpen.1871
Creator	Arnaldo, Av, Calder, Philip Susana, Raquel Torrinhas, M Torrinhas, Raquel Waitzberg, Dan
Source	Medline; PMC
abstract	In this letter we discuss the proposition of Bristian BR (2020) to use the intravenous administration of fish oil emulsions in critically ill COVID‐19. We consider that immune modulatory properties of eicosapentaenoic (EPA) and docosahexaenoic (DHA) acids, rapidly provided in high amounts by fish oil emulsion, may be important to change the course of COVID‐19's death pathway. Prescriptions should be based on body weight (e.g. 0.2 g pure FOLE/kg body weight/day) and also should consider combining the parenteral administration of fish oil emulsion to low oral aspirin intake, in order to trigger resolvin synthesis from EPA and DHA. This article is protected by copyright. All rights reserved
has issue date	2020-05-28(xsd:dateTime)
bibo:doi	10.1002/jpen.1933
bibo:pmid	32463483
has license	no-cc
sha1sum (hex)	2c73b94e0d91c3706fa3ea2f413f15f43e90bfbd
schema:url	https://doi.org/10.1002/jpen.1933
resource representing a document's title	Letter to the Editor in relation to Bistrian BR. Parenteral fish oil emulsions in critically ill COVID‐19 emulsions [published online ahead of print, 2020 May 8]. JPEN J Parenter Enteral Nutr. 2020;10.1002/jpen.1871
has PubMed Central identifier	PMC7283760
has PubMed identifier	32463483
schema:publication	JPEN J Parenter Enteral Nutr
resource representing a document's body	covid:2c73b94e0d91c3706fa3ea2f413f15f43e90bfbd#body_text
is schema:about of	named entity 'emulsion' named entity 'ACIDS' named entity 'MAY BE' named entity 'RIGHTS' named entity 'AMOUNTS' named entity 'PROVIDED' named entity 'FISH OIL' named entity 'rapidly' named entity 'COVID-19' named entity 'emulsion' named entity 'intravenous administration' named entity 'COVID-19' named entity 'fish oil' named entity 'protected by copyright' named entity 'DHA' named entity 'obese' named entity 'arteriosclerosis' named entity 'ACE2' named entity 'resolvins' named entity 'critically ill' named entity 'FOLE' named entity 'aspirin' named entity 'NETs' named entity 'EPA' named entity 'aspirin' named entity 'EPA' named entity 'underweight' named entity 'DHA' named entity 'fish oil' named entity 'clinically relevant' named entity 'aspirin' named entity 'receptor' named entity 'bioactive' named entity 'exogenous' named entity 'aspirin' named entity 'membrane lipid' named entity 'ischaemic' named entity 'inflammatory cytokines' named entity 'fish oil' named entity 'EPA' named entity 'hyperinflammation' named entity 'lipid emulsion' named entity 'high-risk' named entity 'EPA' named entity 'inflammatory' named entity 'cell receptor' named entity 'inflammation' named entity 'FOLE' named entity 'COVID-19' named entity 'DHA' named entity 'FOLE' named entity 'COVID-19' named entity 'therapeutic target' named entity 'body weight' named entity 'FOLE' named entity 'lipid' named entity 'oncologic' named entity 'FOLE' named entity 'body weight' named entity 'COVID-19' named entity 'FOLE' named entity 'fish oil' named entity 'Dutch' named entity 'EPA' named entity 'hyperinflammation' named entity 'DHA' named entity 'proinflammatory' named entity 'inflammation' named entity 'COVID-19' named entity 'intravenous' named entity 'diabetic' named entity 'abnormal blood clotting' named entity 'upper gastrointestinal' named entity 'immune modulatory' named entity 'inflammatory'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software